Bedrijfsoverzicht
Iterum Therapeutics plc is a pharmaceutical enterprise focused on the development and commercialization of treatments specifically designed for drug-resistant bacterial infections, with operations spanning Ireland, Bermuda, and the United States. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player in the realm of antibiotic therapies and infectious disease management. As of the latest data, the company holds a market capitalization of $1.60M and employs a workforce of 9 individuals, while generating an annual revenue of $390,000. These valuation and revenue figures indicate that Iterum Therapeutics is currently a micro-cap entity with minimal market footprint, suggesting it is in an early-stage development or pre-commercialization phase where capital intensity outweighs current income generation. The substantial disparity between the company's operational scale and its cash requirements implies a high degree of financial risk associated with early-stage biotechnology ventures.
Financiële gezondheid
The company reported a revenue of $390,000 over the trailing twelve months, yet this figure stands in stark contrast to a net income of $-26,961,000, revealing an extremely heavy cost structure dominated by research and development expenses or other overheads not yet offset by commercial sales. This significant gap between gross revenue and net loss underscores the typical financial profile of a biotechnology firm that has not yet achieved a profitable revenue stream. The free cash flow stands at $-13,851,125, indicating that the company is burning through its available liquidity to fund its operations and pipeline advancements. Despite the negative free cash flow, the company maintains a cash balance of $11.00M, which provides a temporary runway for operations, although it is insufficient to cover its total debt obligation of $33.73M without external financing. The balance sheet is heavily leveraged, as evidenced by the debt-to-equity ratio listed as N/A due to negative equity, and the negative price-to-book ratio of -0.20, signaling that liabilities exceed the book value of assets. Short-term liquidity appears manageable based on a current ratio of 2.13, suggesting the company holds more than twice the current assets needed to settle its short-term liabilities. However, the return on equity is N/A due to the negative equity position, and the return on assets stands at -53.3%, which reveals that the management team is currently destroying value rather than generating returns on the capital deployed in the business.
Waarderingsbeoordeling
The valuation metrics for Iterum Therapeutics reflect its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -0.05, implying that earnings-based valuation methods are not applicable due to the company's current losses. The price-to-book ratio is -0.20, which indicates that the market is valuing the company at a fraction of its negative book value, a common occurrence for distressed or pre-profitable biotech stocks with intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 4.10 and an EV/EBITDA of -1.31 suggest that investors are pricing the stock based on its potential future commercialization prospects rather than current financial performance. The stock's price volatility is extreme, trading within a 52-week range between a low of $0.03 and a high of $1.42, meaning the current market price sits at a significant discount relative to the recent 52-week high. The beta of 3.01 indicates that the stock's price is highly volatile and moves with three times the magnitude of the broader market, exposing holders to substantial price fluctuations during periods of market stress.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is no historical data available to calculate growth rates, likely due to the company's very recent inception or lack of consistent reporting history. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue because the company has not yet established a baseline of profitable operations to compare against. As a non-dividend payer, the company does not distribute any income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Instead of paying dividends, the company is in a phase where all available earnings and cash reserves are reinvested entirely into research, development, and operational costs to advance its drug pipeline. The overall growth and income profile of Iterum Therapeutics is characterized by a complete absence of current income generation, with all financial metrics pointing toward a speculative investment thesis reliant on future product approvals and commercial success rather than existing cash flows or dividend distributions.